Inherited endocrinopathies: An update

Molecular Genetics and Metabolism

Volumn 94, Issue 3, 2008, Pages 271-282

  Lewis, Catherine E ^a   Yeh, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Medullary thyroid cancer; Menin; Multiple endocrine neoplasia type 1 (MEN 1); Multiple endocrine neoplasia type 2 (MEN 2A and MEN 2B); Neurofibromatosis type 1 (NF 1); Pancreatic neuroendocrine tumors; Paraganglioma syndromes; Pheochromocytoma; RET; Succinate dehydrogenase subunit B and D (SDHB and SDHD); von Hippel Lindau disease (VHL)

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN; CEP 751; FLUORINE 18; FLUORODIHYDROXYPHENYLALANINE F 18; IMATINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRACER; TUMOR MARKER; VANDETANIB;

ADRENALECTOMY; AUTOSOMAL DOMINANT INHERITANCE; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ENDOCRINE DISEASE; FAMILIAL CANCER; GENE MUTATION; GENETIC DISORDER; HUMAN; HYPERTENSION; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS DISEASE; PANCREATICODUODENECTOMY; PARAGANGLIOMA; PARATHYROID DISEASE; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIPPLE SYNDROME; SYNDROME DELINEATION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR DIAGNOSIS; TUMOR SCINTISCANNING; VON HIPPEL LINDAU DISEASE;

CARCINOMA, MEDULLARY; COMORBIDITY; ENDOCRINE SYSTEM DISEASES; GENETIC DISEASES, INBORN; HUMANS; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PARAGANGLIOMA; PHEOCHROMOCYTOMA; THYROID NEOPLASMS;

EID: 44649167602     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.03.006     Document Type: Review

References (83)

1. Doherty G.M. Multiple endocrine neoplasia type 1. J. Surg. Oncol. 89 (2005) 143-150
2. Wilkinson S., Teh B.T., Davey K.R., McArdle J.P., Young M., and Shepherd J.J. Cause of death in multiple endocrine neoplasia type 1. Arch. Surg. 128 (1993) 683-690
3. Doherty G.M., Olson J.A., Frisella M.M., Lairmore T.C., Wells Jr. S.A., and Norton J.A. Lethality of multiple endocrine neoplasia type I. World J. Surg. 22 (1998) 581-586
4. Dean P.G., van Heerden J.A., Farley D.R., Thompson G.B., Grant C.S., Harmsen W.S., and Ilstrup D.M. Are patients with multiple endocrine neoplasia type 1 prone to premature death?. World J. Surg. 24 (2000) 1437-1441
5. Glascock M.J., and Carty S.E. Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg. Oncol. 11 (2002) 143-150
6. Thakker R.V., Bouloux P., Wooding C., Chotai K., Broad P.M., Spurr N.K., Besser G.M., and O'Riordan J.L. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N. Engl. J. Med. 321 (1989) 218-224
7. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., Conte-Devolx B., Falchetti A., Gheri R.G., Libroia A., Lips C.J., Lombardi G., Mannelli M., Pacini F., Ponder B.A., Raue F., Skogseid B., Tamburrano G., Thakker R.V., Thompson N.W., Tomassetti P., Tonelli F., Wells Jr. S.A., and Marx S.J. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86 (2001) 5658-5671
8. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., and Peacock M.J. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88 (2003) 5644-5649
9. Silverberg S.J., Bone III H.G., Marriott T.B., Locker F.G., Thys-Jacobs S., Dziem G., Kaatz S., Sanguinetti E.L., and Bilezikian J.P. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. 337 (1997) 1506-1510
10. Le Bodic M.F., Heymann M.F., Lecomte M., Berger N., Berger F., Louvel A., De Micco C., Patey M., De Mascarel A., Burtin F., and Saint-Andre J.P. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type 1. Am. J. Surg. Pathol. 20 (1996) 1378-1384
11. Norton J.A., and Jensen R.T. Multiple endocrine neoplasia. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and Practice of Oncology (1997), Lippincott-Raven, Philadelphia 1723-1729
12. Weber H.C., Venzon D.J., Lin J.T., Fishbein V.A., Orbuch M., Strader D.B., Gibril F., Metz D.C., Fraker D.L., Norton J.A., and Jensen R.T. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108 (1995) 1637-1649
13. Wiedenmann B., Jensen R.T., Mignon M., Modlin C.I., Skogseid B., Doherty G., and Oberg K. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J. Surg. 22 (1998) 309-318
14. Lowney J.K., Frisella M.M., Lairmore T.C., and Doherty G.M. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 124 (1998) 1043-1048
15. Skogseid B., Oberg K., Eriksson B., Juhlin C., Granberg D., Akerstrom G., and Rastad J. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J. Surg. 20 (1996) 872-876
16. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.J., Gibril F., and Jensen R.T. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann. Surg. 234 (2001) 495-505
17. Yang Y., and Hua X. In search of tumor suppressing functions of menin. Mol. Cell Endocrinol. 265 (2007) 34-41
18. Ratineau C., Bernard C., Poncet G., Blanc M., Josso C., Fontaniere S., Calender A., Chayvialle J.A., Zhang C.X., and Roche C. Reduction of menin expression enhances cell proliferation and is tumorigenic in intestinal epithelial cells. J. Biol. Chem. 279 (2004) 24477-24484
19. Kaji H., Canaff L., Lebrun J.J., Goltzman D., and Hendy G.N. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc. Natl. Acad. Sci. USA 98 (2001) 3837-3842
20. Zou L., and Elledge S.J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300 (2003) 1542-1548
21. Marx S.J. Multiple endocrine neoplasia type 1. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 943-966
22. Teh B.T., Kytölä S., Farnebo F., Bergman L., Wong F.K., Weber G., Hayward N., Larsson C., Skogseid B., Beckers A., Phelan C., Edwards M., Epstein M., Alford F., Hurley D., Grimmond S., Silins G., Walters M., Stewart C., Cardinal J., Khodaei S., Parente F., Tranebjærg L., Jorde R., Menon J., Khir A., Tan T.T., Chan S.P., Zaini A., Khalid B.A.K., Sandelin K., Thompson N., Brandi M.-L., Warth M., Stock J., Leisti J., Cameron D., Shepherd J.J., Öberg K., Nordenskjöld M., and Salmela P. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J. Clin. Endocrinol. Metab. 83 (1998) 2621-2626
23. Agarwal S.K., Kester M.B., Debelenko L.V., Heppner C., Emmert-Buck M.R., Skarulis M.C., Doppman J.L., Kim Y.S., Lubensky I.A., Zhuang Z., Green J.S., Guru S.C., Manickam P., Olufemi S.E., Liotta L.A., Chandrasekharappa S.C., Collins F.S., Spiegel A.M., Burns A.L., and Marx S.J. Germline mutations of the MENI gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 6 (1997) 1169-1175
24. Bassett J.H., Forbes S.A., Pannett A.A., Lloyd S.E., Christie P.T., Wooding C., Harding B., Besser G.M., Edwards C.R., Monson J.P., Sampson J., Wass J.A., Wheeler M.H., and Thakker R.V. Characterization of mutations in patients with multiple endocrine neoplasia type I. Am. J. Hum. Genet. 62 (1998) 232-244
25. Mutch M.G., Dilley W.G., Sanjurjo F., DeBenedetti M.K., Doherty G.M., Wells Jr. S.A., Goodfellow P.J., and Lairmore T.C. Germline mutations in the multiple endocrine neoplasia type 1 gene: Evidence for frequent splicing defects. Hum. Mutat. 13 (1999) 175-185
26. Balogh K., Patocs A., Majnik J., Racz K., and Hunyady L. Genetic screening methods for the detection of mutations responsible for multiple endocrine neoplasia type 1. Mol. Genet. Metab. 83 (2004) 74-81
27. Cardinal J.W., Bergman L., Hayward N., Sweet A., Warner J., Marks L., Learoyd D., Dwight T., Robinson B., Epstein M., Smith M., Teh B.T., Cameron D.P., and Prins J.B. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J. Med. Genet. 42 (2005) 69-74
28. Klein R.D., Salih S., Bessoni J., and Bale A.E. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet. Med. 7 (2005) 131-138
29. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., Fend F., Graw J., and Atkinson M.J. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA 103 (2006) 15558-15563
30. Georgitsi M., Raitila A., Karhu A., van der Luijt R.B., Aalfs C.M., Sane T., Vierimaa O., Mäkinen M.J., Tuppurainen K., Paschke R., Gimm O., Koch C.A., Gündogdu S., Lucassen A., Tischkowitz M., Izatt L., Aylwin S., Bano G., Hodgson S., De Menis E., Launonen V., Vahteristo P., and Aaltonen L.A. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab. 92 (2007) 3321-3325
31. Shapiro S.E., Cote G.C., Lee J.E., Gagel R.F., and Evans D.B. The role of genetics in the surgical management of familial endocrinopathy syndromes. J. Am. Coll. Surg. 197 (2003) 818-831
32. Herfarth K.K., and Wells Jr. S.A. Parathyroid glands and the multiple endocrine neoplasia syndromes and familial hypocalciuric hypercalcemia. Semin. Surg. Oncol. 13 (1997) 114-124
33. Howe J.R., Norton J.A., and Wells Jr. S.A. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114 (1993) 1070-1077
34. Khairi M.R., Dexter R.N., Burzynski N.J., and Johnston Jr. C.C. Mucosal neuroma, pheochromocytoma and medullary thyroid carcinoma: multiple endocrine neoplasia type 3. Medicine (Baltimore) 54 (1975) 89-112
35. Chi D.D., and Moley J.F. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninmia. Surg. Oncol. Clin. North Am. 7 (1998) 681-706
36. Wells Jr. S.A., Chi D.D., Toshima K., Dehner L.P., Coffin C.M., Dowton S.B., Ivanovich J.L., DeBenedetti M.K., Dilley W.G., Moley J.F., Norton J.A., and Donis-Keller H. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 220 (1994) 237-247
37. Kouvaraki M.A., Shapiro S.E., Perrier N.D., Cote G.J., Gagel R.F., Hoff A.O., Sherman S.I., Lee J.E., and Evans D.B. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 (2005) 531-544
38. Yen T.W., Shapiro S.E., Gagel R.F., Sherman S.I., Lee J.E., and Evans D.B. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134 (2003) 890-899
39. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
40. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
41. Cohen M.S., Hussain H.B., and Moley J.F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 (2002) 960-966
42. Polverino A., Coxon A., Starnes C., Diaz Z., DeMelfi T., Wang L., Bready J., Estrada J., Cattley R., Kaufman S., Chen D., Gan Y., Kumar G., Meyer J., Neervannan S., Alva G., Talvenheimo J., Montestruque S., Tasker A., Patel V., Radinsky R., and Kendall R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66 (2006) 8715-8721
43. Strock C.J., Park J.I., Rosen M., Dionne C., Ruggeri B., Jones-Bolin S., Denmeade S.R., Ball D.W., and Nelkin B.D. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 63 (2003) 5559-5563
44. Herbst R.S., Heymach J.V., O'Reilly M.S., Onn A., and Ryan A.J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert. Opin. Investig. Drugs. 16 (2007) 239-249
45. Wells Jr. S.A., Gosnell J.E., Gagel R.F., Moley J.F., Pfister D.G., Sosa J.A., Skinner M., Krebs A., Hou J., and Schlumberger M. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. (abstract). J. Clin. Oncol. 25 (2007) 6018
46. Sherman S.I., Schlumberger M.J., Droz J., Hoffmann M., Wirth L., Bastholt L., Martins R.G., Licitra L., Shi Y., and Stepan D.E. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). (abstract). J. Clin. Oncol. 25 (2007) 6017
47. Murakumo Y., Jijiwa M., Asai N., Ichihara M., and Takahashi M. RET and neuroendocrine tumors. Pituitary 9 (2006) 179-192
48. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., Golden J.P., Creedon D.J., Johnson Jr. E.M., and Milbrandt J. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996) 467-470
49. Milbrandt J., de Sauvage F.J., Fahrner T.J., Baloh R.H., Leitner M.L., Tansey M.G., Lampe P.A., Heuckeroth R.O., Kotzbauer P.T., Simburger K.S., Golden J.P., Davies J.A., Vejsada R., Kato A.C., Hynes M., Sherman D., Nishimura M., Wang L.C., Vandlen R., Moffat B., Klein R.D., Poulsen K., Gray C., Garces A., Henderson C.E., Phillips H.S., and Johnson Jr. E.M. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20 (1998) 245-253
50. Baloh R.H., Tansey M.G., Lampe P.A., Fahrner T.J., Enomoto H., Simburger K.S., Leitner M.L., Araki T., Johnson Jr. E.M., and Milbrandt J. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21 (1998) 1291-1302
51. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., van Amstel H.K., Lips C.J., Nishisho I., Takai S.I., Marsh D.J., Robinson B.G., Frank-Raue K., Raue F., Xue F., Noll W.W., Romei C., Pacini F., Fink M., Niederle B., Zedenius J., Nordenskjold M., Komminoth P., Hendy G.N., and Mulligan L.M. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 (1996) 1575-1579
52. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H., and Di Fiore P.P. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 (1995) 381-383
53. Hofstra R.M., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Hoppener J.W., van Amstel H.K., Romeo G., Lips C.J., and Buys C.H. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
54. Arighi E., Borrello M.G., and Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 16 (2005) 441-467
55. Wells Jr. S.A., and Skinner M.A. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp. Clin. Endocrinol. Diabetes 106 (1998) 29-34
56. Gagel RF R.F., Tashjian Jr. A.H., Cummings T., Papathanasopoulos N., Kaplan M.M., DeLellis R.A., Wolfe H.J., and Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N. Engl. J. Med. 318 (1988) 478-484
57. Raue F., Kraimps J.L., Dralle H., Cougard H.P., Proye C., Frilling A., Limbert E., Llenas L.F., and Niederle B. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J. Intern. Med. 238 (1995) 369-373
58. Zelinka T., Eisenhofer G., and Pacak K. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress 10 (2007) 195-203
59. P Neumann H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., Eng C., Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M., Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C., Eng C., and Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346 (2002) 1459-1466
60. Bauters C., Vantyghem M.C., Leteurtre E., Odou M.F., Mouton C., Porchet N., Wemeau J.L., Proye C., and Pigny P. Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes. J. Med. Genet. 40 (2003) e75
61. Astuti D., Hart-Holden N., Latif F., Lalloo F., Black G.C., Lim C., Moran A., Grossman A.B., Hodgson S.V., Freemont A., Ramsden R., Eng C., Evans D.G., and Maher E.R. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and pheochromocytoma susceptibility. Clin. Endocrinol. (Oxf) 59 (2003) 728-733
62. Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., Bertherat J., Burgess J., Byth K., Croxson M., Dahia P.L., Elston M., Gimm O., Henley D., Herman P., Murday V., Niccoli-Sire P., Pasieka J.L., Rohmer V., Tucker K., Jeunemaitre X., Marsh D.J., Plouin P.F., and Robinson B.G. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab. 91 (2006) 827-836
63. Evans D.B., Lee J.E., Merrell R.C., and Hickey R.C. Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol. Metab. Clin. North Am. 23 (1994) 167-176
64. Lee J.E., Curley S.A., Gagel R.F., Evans D.B., and Hickey R.C. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120 (1996) 1064-1070
65. Zbar B., Kishida T., Chen F., Schmidt L., Maher E.R., Richards F.M., Crossey P.A., Webster A.R., Affara N.A., Ferguson-Smith M.A., Brauch H., Glavac D., Neumann H.P., Tisherman S., Mulvihill J.J., Gross D.J., Shuin T., Whaley J., Seizinger B., Kley N., Olschwang S., Boisson C., Richard S., Lips C.H., Linehan W.M., and Lerman M. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8 (1996) 348-357
66. Maher E.R., Webster A.R., Richards F.M., Green J.S., Crossey P.A., Payne S.J., and Moore A.T. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J. Med. Genet. 33 (1996) 328-332
67. Ong K.R., Woodward E.R., Killick P., Lim C., Macdonald F., and Maher E.R. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum. Mutat. 28 (2007) 143-149
68. Stolle C., Glenn G., Zbar B., Humphrey J.S., Choyke P., Walther M., Pack S., Hurley K., Andrey C., Klausner R., and Linehan W.M. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12 (1998) 417-423
69. Chen F., Kishida T., Yao M., Hustad T., Glavac D., Dean M., Gnarra J.R., Orcutt M.L., Duh F.M., Glenn G., Green J., Hsia Y.E., Lamiell J., Li H., Wei M.H., Schmidt L., Tory K., Kuzmin I., Stackhouse T., Latif F., Linehan W.M., Lerman M., and Zbar B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5 (1995) 66-75
70. Bausch B., Borozdin W., Mautner V.F., Hoffmann M.M., Boehm D., Robledo M., Cascon A., Harenberg T., Schiavi F., Pawlu C., Peczkowska M., Letizia C., Calvieri S., Arnaldi G., Klingenberg-Noftz R.D., Reisch N., Fassina A., Brunaud L., Walter M.A., Mannelli M., MacGregor G., Palazzo F.F., Barontini M., Walz M.K., Kremens B., Brabant G., Pfaffle R., Koschker A.C., Lohoefner F., Mohaupt M., Gimm O., Jarzab B., McWhinney S.R., Opocher G., Januszewicz A., Kohlhase J., Eng C., Neumann H.P., and European-American Phaeochromocytoma Registry Study Group. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J. Clin. Endocrinol. Metab. 92 (2007) 2784-2792
71. Favier J., Brière J.J., Strompf L., Amar L., Filali M., Jeunemaitre X., Rustin P., Gimenez-Roqueplo A.P., and PGL.NET Network. Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm. Res. 63 (2005) 171-179
72. Baysal B.E. Hereditary paraganglioma targets diverse paraganglia. J. Med. Genet. 39 (2002) 617-622
73. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., Buchta M., Franke G., Klisch J., Bley T.A., Hoegerle S., Boedeker C.C., Opocher G., Schipper J., Januszewicz A., and Eng C. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 (2004) 943-951
74. Schiavi F., Boedeker C.C., Bausch B., Peçzkowska M., Gomez C.F., Strassburg T., Pawlu C., Buchta M., Salzmann M., Hoffmann M.M., Berlis A., Brink I., Cybulla M., Muresan M., Walter M.A., Forrer F., Välimäki M., Kawecki A., Szutkowski Z., Schipper J., Walz M.K., Pigny P., Bauters C., Willet-Brozick J.E., Baysal B.E., Januszewicz A., Eng C., Opocher G., Neumann H.P., and for the European-American Paraganglioma Study Group. Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the SDHC Gene. JAMA 294 (2005) 2057-2063
75. Kudva Y.C., Sawka A.M., and Young Jr. W.F. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo clinic experience. J. Clin. Endocrinol. Metab. 88 (2003) 4533-4539
76. Neumann H.P., Berger D.P., Sigmund G., Blum U., Schmidt D., Parmer R.J., Volk B., and Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N. Engl. J. Med. 329 (1993) 1531-1538
77. Varghese J.C., Hahn P.F., Papanicolaou N., Mayo-Smith W.W., Gaa J.A., and Lee M.J. MR differentiation of pheochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times. Clin. Radiol. 52 (1997) 603-606
78. Brink J., Joegerle S., Klisch J., and Bley T.A. Imaging of pheochromocytoma and paraganglioma. Fam. Can. 4 (2005) 61-68
79. Hoegerle S., Nitzsche E., Altenhoefer C., Ghanem N., Manz T., Brink I., Reincke M., Moser E., and Neumann H.P. Pheochromocytomas: detection with 19F DOPA whole-body PET - initial results. Radiology 222 (2002) 507-512
80. Ilias I., Yu J., Carrasquillo J.A., Chen C.C., Eisenhofer G., Whatley M., McElroy B., and Pacak K. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J. Clin. Endocrinol. Metab. 88 (2003) 4083-4087
81. Ilias I., Shulkin B., and Pacak K. New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends Endocrinol. Metab. 16 (2005) 66-72
82. Gagner M., Breton G., Pharand D., and Pomp A. Is laparoscopic adrenalectomy indicated for pheochromocytoma?. Surgery 120 (1996) 1076-1079
83. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., Farese R.V., Freeman R.S., Carter B.D., Kaelin Jr. W.G., and Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 (2005) 155-167